Nonlinear decline of mini-mental state examination in Parkinson's disease

2010 ◽  
Vol 26 (2) ◽  
pp. 334-337 ◽  
Author(s):  
Dag Aarsland ◽  
Graciela Muniz ◽  
Fiona Matthews
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mental State ◽  
Mini Mental State Examination ◽  
State Examination

scholarly journals Comparing the Montreal Cognitive Assessment with Mini-Mental State Examination in Japanese Parkinson's disease patients

2014 ◽  
Vol 2 (2) ◽  
pp. 44-49 ◽  
Author(s):  
Kouichi Ohta ◽  
Takashi Osada ◽  
Yukito Shinohara ◽  
Norihiro Suzuki ◽  
Kazushi Takahashi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mental State ◽  
Cognitive Assessment ◽  
Mini Mental State Examination ◽  
Montreal Cognitive Assessment ◽  
State Examination

scholarly journals Montreal Cognitive Assessment scale in patients with Parkinson Disease with normal scores in the Mini-Mental State Examination

2019 ◽  
Vol 13 (1) ◽  
pp. 78-81 ◽  
Author(s):  
Krisly Arguedas Vásquez ◽  
Erick Miranda Valverde ◽  
Daniel Valerio Aguilar ◽  
Henri-Jacques Hernández Gabarain
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mental State ◽  
Cognitive Assessment ◽  
Mini Mental State Examination ◽  
Montreal Cognitive Assessment ◽  
Screening Tests ◽  
Study Results ◽  
State Examination

ABSTRACT. Several screening tests have been used for cognitive evaluation in Parkinson’s disease (PD). Objective: To evaluate the usefulness of the Montreal Cognitive Assessment (MoCA) in patients with Parkinson’s disease and no cognitive impairment complaints. Methods: A total of 40 PD patients with no complaints of cognitive problems were included. Patients were selected using the Mini-Mental State Examination (MMSE) and the MoCA was then administered. Results: 80% of patients exhibited Mild Cognitive Impairment (MCI) according to the MoCA. Statistically significant differences in visuospatial, attention and delayed recall functions were evident between the normal and abnormal MoCA groups. Conclusion: The study results suggest that MoCA may be a good screening test in patients with PD who do not present cognitive complaints.

scholarly journals Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels

2020 ◽  
Vol 48 (7) ◽  
pp. 030006052092244
Author(s):  
Jinzhong Huang ◽  
Wei Hong ◽  
Zhilong Yang ◽  
Jian Ding ◽  
Yi Ren
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mental State ◽  
Mini Mental State Examination ◽  
Control Group ◽  
Study Group ◽  
Tnf Α ◽  
State Examination

Purpose To investigate the efficacy of combining the dopamine receptor agonist pramipexole with levodopa for Parkinson’s disease (PD) treatment and to measure their effects on quality of life and tumor necrosis factor (TNF)-α levels in PD patients. Basic Procedure In total, 160 PD patients who were admitted to our hospital were equally randomized into a control treatment group (levodopa alone) and the study group (pramipexole combined with levodopa). Both groups were treated for 12 weeks. Findings After treatment, scores from the Unified Parkinson’s Disease Rating Scales (1–3), the Hamilton Depression Scale, and the Parkinson’s Disease Questionnaire (PDQ-39) were significantly decreased in both groups, whereas Mini-Mental State Examination scores were significantly increased. After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group. The incidence of adverse reactions was significantly lower in the study group than in the control group. Furthermore, after treatment, serum TNF-α levels were significantly decreased in both groups compared with pre-treatment levels. Conclusion Pramipexole combined with levodopa relieved PD symptoms and improved the quality of life of PD patients, potentially by suppressing serum TNF-α levels.

scholarly journals Association of SNCA Parkinson's Disease Risk Polymorphisms With Disease Progression in Newly Diagnosed Patients

2021 ◽  
Vol 11 ◽  
Author(s):  
Aleksandra A. Szwedo ◽  
Camilla Christina Pedersen ◽  
Anastasia Ushakova ◽  
Lars Forsgren ◽  
Ole-Bjørn Tysnes ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Confidence Interval ◽  
Disease Progression ◽  
Mental State ◽  
Mini Mental State Examination ◽  
Rating Scale ◽  
Minor Effect ◽  
The Impact ◽  
State Examination

Objectives: To evaluate the impact of SNCA polymorphisms originally identified as risk factors for Parkinson's disease (PD) on the clinical presentation and progression of the disease in a large cohort of population-based patients with incident PD.Methods: Four hundred thirty-three patients and 417 controls from three longitudinal cohorts were included in the study. Disease progression was recorded annually for up to 9 years using the Unified Parkinson's Disease Rating Scale (UPDRS) or Mini-Mental State Examination. Genotypes for five variants within the SNCA locus (rs2870004, rs356182, rs5019538, rs356219, and rs763443) were determined. We studied the association between each variant and disease progression using linear mixed-effects regression models.Results: The clinical profile of the patients with PD at the point of diagnosis was highly uniform between genotype groups. The rs356219-GG genotype was associated with a higher UPDRS II score than A-allele carriers (β = 1.52; 95% confidence interval 0.10–2.95; p = 0.036), but no differences were observed in the rate of progression of the UPDRS II scores. rs356219-GG was also associated with a faster annual change in Mini-Mental State Examination score compared with A-carriers (β = 0.03; 95% confidence interval 0.00–0.06; p = 0.043).Conclusions: We show that the known PD-risk variant rs356219 has a minor effect on modifying disease progression, whereas no differences were associated with rs2870004, rs356182, rs5019538, and rs763443. These findings suggest that SNCA variants associated with PD risk may not be major driving factors to the clinical heterogeneity observed for PD.

Sign in / Sign up

Export Citation Format

Share Document